首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 糖尿病 > 美國治療糖尿病產品線藥品的發展前景
產業/市場分類
製藥 (4452)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (167)
神經疾病 (175)
骨頭疾病治療 (40)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (315)
精神病 (80)
製藥企業 (500)
糖尿病 (157)
癌症 (837)
藥物開發 (1246)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

美國治療糖尿病產品線藥品的發展前景

U.S. Diabetes Pipeline Outlook

出版商 Frost & Sullivan
出版日期 2006年11月 商品編碼 47210
內容資訊 英文 72 Pages
價格
US $ 6000 Web Access (Regional License)
US $ 6500 Hard Copy & Web Access (Regional License)


美國治療糖尿病產品線藥品的發展前景 是由出版商Frost & Sullivan在2006年11月所出版的。 這份英文市場調查報告書包含72 Pages 價格從美金6000起跳。

目錄

Abstract

This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.

Table of Contents

1 EXECUTIVE SUMMARY

  • Executive Summary
    • Introduction

2 MARKET INTRODUCTION

  • Research Scope and Methodology
    • Scope and Segmentation
    • Research Methodology
  • Diabetes Overview
    • Introduction
    • Types of Diabetes
    • Prevalence
    • Incidence
    • Current Treatment
  • Pipeline Competitive Analysis
    • Introduction
    • Key Pipeline Companies
    • Areas of Opportunity

3 GLP-1 AGONISTS

  • Introduction
    • GLP-1 Agonist Dynamics
  • GLP-1 Agonists Pipeline Analysis
    • Byetta - Amylin & Eli Lilly
    • GLP-1 Agonist Pipeline

4 PULMONARY INSULIN

  • Introduction
    • Pulmonary Insulin Dynamics
  • Pulmonary Insulin Analysis
    • Exubera - Pfizer & Nektar
    • Pulmonary Insulin Pipeline

5 DPP-IV INHIBITORS

  • Introduction
    • DPP-IV Dynamics
  • DPP-IV Pipeline Analysis
    • Pipeline Analysis

6 PPAR MODULATORS

  • Introduction
    • PPAR Dynamics
  • PPAR Pipeline Analysis
    • PPAR Pipeline
    • Discontinued PPAR Modulators

7 OTHER PIPELINE EFFORTS

  • Introduction
    • Other Development Efforts
  • Pipeline Overviews
    • Other Insulin Pipeline
    • Other OAD Pipeline
    • Other IAD Pipeline

8 APPENDIX

  • Decision Support Databases
    • Incidence of Diabetes
    • Prevalence of Diabetes
    • Diabetes Prevalence as a Percentage of Total Population
    • Diabetes Foot Ulcer Prevalence as a Percentage of Total Population
    • Total Population
Back to Top